Loading
Vorinostat (Zolinza) was the first drug of its kind, a capsule that loosens the chemical packaging of DNA. It treats the skin disease of cutaneous T-cell lymphoma after two other treatments have failed.
Vorinostat was approved by the FDA in October 2006 for cutaneous manifestations of cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease on or after two systemic therapies, on two open-label studies (response rate about 30% in the pivotal single-arm study of 74 patients). It was the first histone deacetylase inhibitor approved for any cancer and remains a standard option in refractory mycosis fungoides and Sezary syndrome; a European application was withdrawn and it is not authorised in the EU. Fatigue, diarrhoea, thrombocytopenia, taste change and QT prolongation are the main adverse effects; thromboembolism is a class warning.
Inhibits class I (HDAC1, 2, 3) and class II (HDAC6) histone deacetylases at nanomolar concentrations, causing histone hyperacetylation, re-expression of silenced genes, cell-cycle arrest and apoptosis. Connects to Histone deacetylases (HDAC).
1.Vorinostat slips into a pocket on Histone deacetylases (HDAC).
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2006 | Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Vorinostat" OR ABSTRACT:"Vorinostat" OR TITLE:"Zolinza" OR ABSTRACT:"Zolinza" OR TITLE:"SAHA" OR ABSTRACT:"SAHA" OR TITLE:"Suberoylanilide hydroxamic acid" OR ABSTRACT:"Suberoylanilide hydroxamic acid") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vorinostat, not a curated reading list.
Shares MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma, MAVORIC, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Histone deacetylases (HDAC), Romidepsin, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma, MAVORIC, Mycosis fungoides, Sezary syndrome.
Shares Histone deacetylases (HDAC), Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Romidepsin, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Histone deacetylases (HDAC), Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Bexarotene, Mycosis fungoides, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Bexarotene, Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).